Comparison Of DIR-MRI And DCE-MRI In Detection Of Prostate Cancer: A Pilot Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a pilot study taking place at University Hospitals of North Midlands NHS Trust. Patients referred for MRI for possible prostate cancer will be invited to take part in the study. Following consent, participants will have an additional MRI sequence performed during their routine MRI called Double Inversion Magnetic Resonance Imaging (DIR-MRI).

Participants scan images and prostate biopsy histology report (if applicable) will be reviewed by the research team.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma

NCT00230386

Prostatic Neoplasms

COMPLETED PHASE1/PHASE2

Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer

NCT00082147

Prostate Cancer

COMPLETED NA

Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

NCT03180398

Prostate Cancer

TERMINATED NA

Magnetic Resonance Imaging to Evaluate Prostate Cancer

NCT00182624

Prostatic Neoplasms

COMPLETED

Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning

NCT02470910

Prostate Cancer Adenocarcinoma of the Prostate Stage I Adenocarcinoma of the Prostate Stage II +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a pilot study taking place at University Hospitals of North Midlands NHS Trust. Patients referred for MRI for possible prostate cancer will be invited to take part in the study. Following consent, participants will have an additional MRI sequence performed during their routine MRI called Double Inversion Magnetic Resonance Imaging (DIR-MRI). Participants scan images and prostate biopsy histology report (if applicable) will be reviewed by the research team. The research team will look at the variability of LNR score amongst the two scan typed and the DCE-MRI and DIR-MRI images will be correlated with biopsy results to give an indication of the accuracy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of the Prostate

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DIR-MRI

Participants will have Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) as well as the standard Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)

Group Type OTHER

Magnetic Resonance Imaging

Intervention Type OTHER

Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnetic Resonance Imaging

Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients referred for prostate MRI for possible prostate cancer
* Safe to undergo an MRI scan
* Able to give informed consent

Exclusion Criteria

* MRI referrals where prostate cancer is not the question
* Patients who are not safe to undergo an MRI scan
* Patients who have undergone prostate biopsy in the previous 10 weeks
* Patients unable to give informed consent

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No